NK cell tumor therapy modulated by UV-inactivated oncolytic herpes simplex virus type 2 and checkpoint inhibitors.

Oncolytic virotherapy is a new and safe therapeutic strategy for cancer treatment. In our previous study, a new type of oncolytic herpes simplex virus type 2 (oHSV2) was constructed. Following the completion of a preclinical study, oHSV2 has now entered into clinical trials for the treatment of melanoma and other solid tumors (NCT03866525). Oncolytic viruses (OVs) are generally able to directly destroy tumor cells and stimulate the immune system to fight tumors. Natural killer (NK) cells are important components of the innate immune system and critical players against tumor cells. But the detailed interactions between oncolytic viruses and NK cells and these interaction effects on the antitumor immune response remain to be elucidated. In particular, the functions of activating surface receptors and checkpoint inhibitors on oHSV2-treated NK cells and tumor cells are still unknown. In this study, we found that UV-oHSV2 potently activates human peripheral blood mononuclear cells, leading to increased antitumor activity in vitro and in vivo. Further investigation indicated that UV-oHSV2-stimulated NK cells release IFN-γ via Toll-like receptor 2 (TLR2)/NF-κB signaling pathway and exert antitumor activity via TLR2. We found for the first time that the expression of a pair of checkpoint molecules, NKG2A (on NK cells) and HLA-E (on tumor cells), is upregulated by UV-oHSV2 stimulation. Anti-NKG2A and anti-HLA-E treatment could further enhance the antitumor effects of UV-oHSV2-stimulated NK92 cells in vitro and in vivo. As our oHSV2 clinical trial is ongoing, we expect that the combination therapy of oncolytic virus oHSV2 and anti-NKG2A/anti-HLA-E antibodies may have synergistic antitumor effects in our future clinical trials.

Wang Y ，Jin J ，Li Y ，Zhou Q ，Yao R ，Wu Z ，Hu H ，Fang Z ，Dong S ，Cai Q ，Hu S ，Liu B ... -  《-》

A novel oncolytic herpes simplex virus type 2 has potent anti-tumor activity.

Zhao Q ，Zhang W ，Ning Z ，Zhuang X ，Lu H ，Liang J ，Li J ，Zhang Y ，Dong Y ，Zhang Y ，Zhang S ，Liu S ，Liu B ... -  《-》

Bispecific Antibody Expressed by an Oncolytic Herpes Simplex Virus Type 2 Can Transform Heterologous T Cells Into Uniform Tumor Killer Cells.

Jin J ，Wang R ，Yang J ，Hu H ，Wang D ，Cai L ，Fang Z ，Dong S ，Hu S ，Wang Y ，Liu B ... -  《-》

Oncolytic virus oHSV2 combined with PD-1/PD-L1 inhibitors exert antitumor activity by mediating CD4 + T and CD8 + T cell infiltration in the lymphoma tumor microenvironment.

Zhang J ，Guo Y ，Fang H ，Guo X ，Zhao L ... -  《-》

UV Light-inactivated HSV-1 Stimulates Natural Killer Cell-induced Killing of Prostate Cancer Cells.

Samudio I ，Hofs E ，Cho B ，Li M ，Bolduc K ，Bu L ，Liu G ，Lam V ，Rennie P ，Jia W ，Elisia I ，Krystal G ... -  《-》